TCGX doubles down on China with $600M Asia-focused fund
Chen Yu's TCGX, a private and public biotech investment firm, is going to invest directly in life sciences companies in China and elsewhere in Asia. The Palo Alto, CA-based firm on Wednesday announced a $600 ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.